Q3 2026 West Pharmaceutical Services Earnings Conference Call - WEST PHARMACEUTICAL SERVICES INC

Financial Performance:

• Q3 2026 revenue reached $874 million, reflecting an 11.9% organic growth rate (8.7% reported) driven by price (approx. 4 percentage points) and volume.
• Adjusted EPS was $2.66, a 36% year-over-year increase and $0.47 above the prior midpoint guidance.
• Gross margin expanded 310 basis points year-over-year to 39.7%, while adjusted operating margins rose 420 basis points to 25.3%.
• Free cash flow for the first nine months totaled $278 million, a 5% decline from 2025 due to higher accounts receivable and inventory, though Q4 is expected to improve.
• Capital expenditures for the first nine months were $125 million; full-year CapEx guidance remains at $215–$220 million (6–8% of revenue).
• Balance sheet strengthened with a revolver upsized to $750 million for five years; YTD share repurchases totaled $685 million (2.4M shares) and dividends paid were $47 million.

Guidance and Future Outlook:

• Full-year 2026 revenue guidance raised to $3.41–$3.42 billion (prior: $3.345–$3.38 billion), implying 11.3%–11.6% organic growth.
• Q4 2026 revenue guidance increased to $820–$830 million, with 6%–7% organic growth expected.
• Full-year 2026 adjusted EPS guidance raised to $9.38–$9.48, representing 29%–30% year-over-year growth.
• Management anticipates full-year operating margin expansion of nearly 300 basis points, significantly outpacing the 100-basis-point long-term growth construct.
• Future outlook assumes a 120 basis point FX benefit and a 160 basis point reported headwind from the SmartDose 3.5 divestiture.

Business Segments and Product Lines:

• Proprietary Products: Delivered 16.6% organic growth, with HPP components growing 20% (now 53% of total company revenue) and HVP devices growing 26% organically (excluding SmartDose 3.5 impact).
• HPP Components: Strong performance across GLP-1s (growing well into the 30s), biologics, and non-GLP-1s; over 200 upgrade projects added this year.
• HVP Devices: Crystal Zenith and Admin Systems drove growth; SmartDose 3.5 revenues ($12M) and SmartDose 3.0 revenues ($100M) are excluded from organic calculations.
• West Vantage: Declined 6.6% organically, slightly better than expected; legacy CGM program roll-off offset new high-value program ramp-ups.
• Standard Products: Revenues grew 3% organically to $163 million.

Market and Competitive Landscape:

• Asia-Pacific region delivered spectacular 42% organic growth, led by India and China, driven by GLP-1 adoption and innovative drug development.
• Americas and EMEA grew 12% and 6% respectively; Europe's growth was partially offset by the West Vantage CGM program decline.
• Regulatory trends, including Annex 1 in Europe and draft HHS guidance in the US regarding contamination, are driving multi-year tailwinds for HPP upgrades globally.
• West maintains a "very short list" status among preferred partners due to technical expertise, regulatory knowledge, and supply chain resilience.

Risks and Challenges:

• SmartDose 3.5 divestiture creates a 290 basis point headwind to reported growth in 2027 due to the removal of revenue base.
• West Vantage segment faces a muted growth trajectory over the next two years due to strategic shifts away from legacy programs.
• FX volatility, specifically recent dollar strengthening, was factored into Q4 guidance.
• Inflationary pressures on the cost base continue, though partially offset by plant efficiencies and price pass-throughs.

Management Commentary and Tone:

• CEO Michelle Lagarde, in her first two months, expressed high confidence in the company's 100-year legacy, emphasizing a mission-driven culture and strong customer relationships.
• Management prioritized "continuous improvement" (automation, digitization) and deepening strategic customer partnerships to anticipate future needs.
• Tone was highly optimistic regarding the GLP-1 and biologics markets, viewing them as durable long-term growth drivers despite generic entry discussions.
• M&A strategy remains disciplined with a high bar for transactions, prioritizing organic growth and portfolio strengthening.

Analyst Questions and Answers:

• Asia Growth: Confirmed drivers include GLP-1 introduction in India/China and early-stage market expansion.
• GLP-1 Outlook: No one-time items in Q3; management remains bullish on long-term growth from new molecules, generics, and multidose shifts, maintaining a robust organic growth view for 2027.
• Margin Expansion: Q3 margin beat was not a one-time event; driven by mix shift to HPP, price, and SG&A leverage; margin expansion is expected to continue.
• Capacity & CapEx: No plans for new geographic sites; investments will focus on existing footprints (HVP finishing) with 18–24 month lead times to come online; CapEx expected to remain in the 6–8% revenue range.
• West Vantage Strategy: Confirmed as a product-led strategy shifting to high-value drug handling; organic focus remains primary over acquisitions.

Other Key Points:

• CEO highlighted a visit to the Eschweiler, Germany site as a prime example of executing efficiency and automation to expand capacity.
• West expects to deliver over 40 billion critical components in 2026, underscoring the scale of patient impact.
• Dividend increased by 18% in the quarter, marking the 34th consecutive year of dividend hikes.
• HPP components now represent over half (53%) of total company revenues, highlighting the shift in the company's revenue mix.